Roche may pull the trigger on a biotech deal as soon as Monday.
Roche is nearing a deal to buy Philadelphia biotechnology company Spark Therapeutics for nearly $5 billion, according to the Wall Street Journal.
It is a move by the Swiss drugmaker to expand its presence treating hemophilia.
There was at least one other bidder for Spark as of Friday, some of the people said, though it isn’t clear who.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Therapies that replace a defective gene with a healthy one are an emerging class of treatment pioneered by companies including Spark. It was founded in 2013 out of gene-therapy research at Children’s Hospital of Philadelphia.
Date: February 25, 2019
Source: Yahoo Finance